	US 12,435,155 B2
	CD137 binding molecules and uses thereof
Alexey Yevgenyevich Berezhnoy, Rockville, MD (US); Gundo Diedrich, Rockville, MD (US); Paul A. Moore, Rockville, MD (US); Ezio Bonvini, Rockville, MD (US); and Kalpana Shah, Rockville, MD (US)
Assigned to MACROGENICS, INC., Rockville, MD (US)
Appl. No. 17/798,285
Filed by MACROGENICS, INC., Rockville, MD (US)
PCT Filed Feb. 16, 2021, PCT No. PCT/US2021/018177 § 371(c)(1), (2) Date Aug. 8, 2022, PCT Pub. No. WO2021/167885, PCT Pub. Date Aug. 26, 2021.
Claims priority of provisional application 63/147,565, filed on Feb. 9, 2021.
Claims priority of provisional application 63/104,685, filed on Oct. 23, 2020.
Claims priority of provisional application 62/980,000, filed on Feb. 21, 2020.
Prior Publication US 2023/0094162 A1, Mar. 30, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/524 (2013.01); C07K 2317/565 (2013.01); C07K 2317/64 (2013.01)]

17 Claims

1. A CD137 Binding Molecule comprising a first binding site that immunospecifically binds to an epitope of CD137, wherein said first binding site comprises a first Light Chain Variable Domain that comprises a CDR_L1, CDR_L2 and CDR_L3, and a first Heavy Chain Variable Domain that comprises a CDR_H1, CDR_H2 and CDR_H3; and wherein:

(A) said first Light Chain Variable Domain CDR_L1, CDR_L2, and CDR_L3 are the Light Chain CDRs of CD137 MAB-6 VL1 (SEQ ID NO:50), CD137 MAB-6 VL2 (SEQ ID NO:55); or CD137 MAB-6 VL3 (SEQ ID NO:56); and

(B) said first Heavy Chain Variable Domain CDR_H1, CDR_H2, and CDR_H3 are the Heavy Chain CDRs of CD137 MAB-6 VH1 (SEQ ID NO:46).